| 产品描述: | MLCK 调节剂;MLCK Modulators;;InformationMavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.In vitroMYK-461 primarily reduces the steady-state ATPase activity by inhibiting the rate of phosphate release of β-cardiac myosin-S1. MYK-461 modulates multiple steps of the myosin chemomechanical cycle. In addition to decreasing the rate-limiting step of the cycle (phosphate release), MYK-461 reduces the number of myosin-S1 heads that can interact with the actin thin filament during transition from the weakly to the strongly bound state without affecting the intrinsic rate. MYK-461 also decreases the rate of myosin binding to actin in the ADP-bound state and the ADP-release rate from myosin-S1 alone.In vivoEarly, chronic administration of MYK-461 suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain. |
| 靶点: |
IC50: 490 nM (bovine cardiac), 711 nM (human cardiac). |
| 体内研究: |
FS 与 Mavacamten 血浆浓度之间存在线性相关性,每增加 100 ng/mL 的 Mavacamten 浓度,FS 降低 4.9%。 Mavacamten 通过降低心肌肌球蛋白重链的三磷酸腺苷酶活性来减少收缩力。长期给予 Mavacamten 可抑制心室肥厚、心肌细胞排列紊乱和心肌纤维化的发生,并减轻携带杂合子人类肌球蛋白重链突变的小鼠中的肥厚性和促纤维化基因表达。 |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.659 ml |
18.293 ml |
36.586 ml |
| 5 mM |
0.732 ml |
3.659 ml |
7.317 ml |
| 10 mM |
0.366 ml |
1.829 ml |
3.659 ml |
| 50 mM |
0.073 ml |
0.366 ml |
0.732 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |